Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.42 |
| ▸ | TUBB | P07437 | 4/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732669 | 0.79 | EP300 (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5143271 | 0.79 | ALDH1A1 (0.40) | SYKTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL19732775 | 0.79 | EP300 (0.43) | SYKSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL20563021 | 0.77 | CYP2A6 (0.40) | SYKTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4306596 | 0.76 | NQO2 (0.39) | SYKSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL5963191 | 0.75 | MCL1 (0.37) | SMN1; SMN2KDM4EALDH1A1NQO1LMNA | |
| SCHEMBL2259297 | 0.73 | ALDH1A1 (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8193889 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EALDH1A1NQO1LMNA | |
| SCHEMBL30503944 | 0.71 | SMN1; SMN2 (0.61) | SYKTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3670609 | 0.71 | SMN1; SMN2 (0.61) | SYKTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020071470-A1 | PHTHALOCYANINE COMPOUND AND USE THEREOF | 山本化成株式会社 | 2020-04-09 | — | — | WO | disclosed |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10227370-B2 | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9770461-B2 | Tailored glycopolymers as anticoagulant heparin mimetics | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| CN-101125833-A | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-7288674-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-30 | — | — | US | disclosed |
| CN-1325446-C | Method and device for producing cyclopropenyl compound | ROHM & HAAS (US) | 2007-07-11 | — | — | CN | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| CN-1457636-A | Method and device for producing cyclopropenyl compound | ROHM & HAAS (US) | 2003-11-26 | — | — | CN | disclosed |
| EP-0283310-B1 | N-BENZHYDRYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
| US-5028610-A | Calcium Channel Blockers | SANKYO COMPANY LIMITED (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0283310-A1 | N-Benzhydryl-substituted heterocyclic derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | SYK 2758/4885TUBB4A 1046/4885TUBB 921/4885 |
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | SYK 964/4885TUBB4A 2445/4885TUBB 1661/4885 |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SYK 964/4885TUBB4A 2445/4885TUBB 1661/4885 |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SYK 964/4885TUBB4A 2445/4885TUBB 1661/4885 |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SYK 964/4885TUBB4A 2445/4885TUBB 1661/4885 |
| US-10227370-B2 | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity | CCL2, CCL5, ACKR3 | SYK 950/4885TUBB4A 2668/4885TUBB 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.